Genetics: Implications for Prevention and Management of Coronary Artery Disease

Journal of the American College of Cardiology

Volumn 68, Issue 25, 2016, Pages 2797-2818

  Assimes, Themistocles L ^a   Roberts, Robert ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

genetic variation; Mendelian randomization; risk scores; sequencing

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROGENESIS; BINDING SITE; CARDIOVASCULAR RISK; COPY NUMBER VARIATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIETARY INTAKE; DNA SEQUENCE; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIATION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; PATIENT IDENTIFICATION; PHYSICAL ACTIVITY; POLLUTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT RESPONSE; DISEASE MANAGEMENT; GENETICS; GENOME-WIDE ASSOCIATION STUDY; METABOLISM; PHENOTYPE; PROCEDURES; RISK FACTOR;

CORONARY ARTERY DISEASE; DISEASE MANAGEMENT; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHENOTYPE; PRIMARY PREVENTION; RISK FACTORS;

EID: 85006391360     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.10.039     Document Type: Review

References (176)

1. 1 Gaziano, T.A., Prabhakaran, D., Gaziano, J.M., Global burden of cardiovascular disease. Mann, D.L., Zipes, D.P., Libby, P., Bonow, R.O., Braunwald, E., (eds.) Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10th edition, 2015, Elsevier/Saunders, Philadelphia, PA, 1–20.
2. 2 Ridker, P.M., Libby, P., Buring, J.E., Risk markers and the primary prevention of cardiovascular disease. Mann, D.L., Zipes, D.P., Libby, P., Bonow, R.O., Braunwald, E., (eds.) Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10th edition, 2015, Elsevier/Saunders, Philadelphia, PA, 891–933.
3. 3 Morrow, D.A., Boden, W.E., Stable ischemic heart disease. Mann, D.L., Zipes, D.P., Libby, P., Bonow, R.O., Braunwald, E., (eds.) Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10th edition, 2015, Elsevier/Saunders, Philadelphia, PA, 1182–1244.
4. 4 Wald, N.J., Law, M.R., A strategy to reduce cardiovascular disease by more than 80%. BMJ, 326, 2003, 1419.
5. 5 Yusuf, S., Hawken, S., Ounpuu, S., et al., for the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004), 937–952.
6. 6 Stampfer, M.J., Hu, F.B., Manson, J.E., et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 343 (2000), 16–22.
7. 7 Tang, L., Patao, C., Chuang, J., et al. Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and Nutrition Examination Survey 2007–2010). Am J Cardiol 112 (2013), 1126–1132.
8. 8 Colantonio, L.D., Bittner, V., Managing residual risk after myocardial infarction among individuals with low cholesterol levels. Endocrinol Metab Clin North Am 45 (2016), 171–184.
9. 9 Shapiro, M.D., Fazio, S., From lipids to inflammation: new approaches to reducing atherosclerotic risk. Circ Res 118 (2016), 732–749.
10. 10 Alfonsi, J.E., Hegele, R.A., Gryn, S.E., Pharmacogenetics of lipid-lowering agents: precision or indecision medicine?. Curr Atheroscler Rep, 18, 2016, 24.
11. 11 Ross, S., Nejat, S., Paré, G., Use of genetic data to guide therapy in arterial disease. J Thromb Haemost 13:Suppl 1 (2015), S281–S289.
12. 12 Stranger, B.E., Forrest, M.S., Dunning, M., et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315 (2007), 848–853.
13. 13 Redon, R., Ishikawa, S., Fitch, K.R., et al. Global variation in copy number in the human genome. Nature 444 (2006), 444–454.
14. 14 Bhangale, T.R., Rieder, M.J., Livingston, R.J., et al. Comprehensive identification and characterization of diallelic insertion-deletion polymorphisms in 330 human candidate genes. Hum Mol Genet 14 (2005), 59–69.
15. 15 Weiner, M.P., Gabriel, S.B., Stephens, J.C., Genetic Variation: A Laboratory Manual. 2007, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
16. 16 Sun, J.X., Helgason, A., Masson, G., et al. A direct characterization of human mutation based on microsatellites. Nat Genet 44 (2012), 1161–1165.
17. 17 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing [Erratum in Nature 2011;473:544]. Nature 467 (2010), 1061–1073.
18. 18 Pritchard, J.K., Are rare variants responsible for susceptibility to complex diseases?. Am J Hum Genet 69 (2001), 124–137.
19. 19 Friedlander, Y., Familial clustering of coronary heart disease: a review of its significance and role as a risk factor for the disease. Goldbourt, U., De Faire, U., Berg, K., (eds.) Genetic Factors in Coronary Heart Disease, 1994, Kluwer Academic, Boston, MA, 37–53.
20. 20 Chow, C.K., Islam, S., Bautista, L., et al. Parental history and myocardial infarction risk across the world: the INTERHEART Study. J Am Coll Cardiol 57 (2011), 619–627.
21. 21 Nielsen, M., Andersson, C., Gerds, T.A., et al. Familial clustering of myocardial infarction in first-degree relatives: a nationwide study. Eur Heart J 34 (2013), 1198–1203.
22. 22 de Faire, U., Pedersen, N., Studies of twins and adoptees in coronary heart disease. Goldbourt, U., De Faire, U., Berg, K., (eds.) Genetic Factors in Coronary Heart Disease, 1994, Kluwer Academic, Boston, MA, 55–68.
23. 23 Zdravkovic, S., Wienke, A., Pedersen, N.L., et al. Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J Intern Med 252 (2002), 247–254.
24. 24 Wienke, A., Holm, N.V., Skytthe, A., et al. The heritability of mortality due to heart diseases: a correlated frailty model applied to Danish twins. Twin Res 4 (2001), 266–274.
25. 25 Marenberg, M.E., Risch, N., Berkman, L.F., et al. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330 (1994), 1041–1046.
26. 26 Hejtmancik, J.F., Brink, P.A., Towbin, J., et al. Localization of gene for familial hypertrophic cardiomyopathy to chromosome 14q1 in a diverse US population. Circulation 83 (1991), 1592–1597.
27. 27 Jarcho, J.A., McKenna, W., Pare, J.A., et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 321 (1989), 1372–1378.
28. 28 Geisterfer-Lowrance, A.A.T., Kass, S., Tanigawa, G., et al. A molecular basis for familial hypertrophic cardiomyopathy: a β cardiac myosin heavy chain gene missense mutation. Cell 62 (1990), 999–1006.
29. 29 Musunuru, K., Kathiresan, S., Genetics of coronary artery disease. Annu Rev Genomics Hum Genet 11 (2010), 91–108.
30. 30 Keramati, A.R., Fathzadeh, M., Go, G.W., et al. A form of the metabolic syndrome associated with mutations in DYRK1B. N Engl J Med 370 (2014), 1909–1919.
31. 31 Mani, A., Radhakrishnan, J., Wang, H., et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315 (2007), 1278–1282.
32. 32 Risch, N.J., Searching for genetic determinants in the new millennium. Nature 405 (2000), 847–856.
33. 33 Risch, N., Merikangas, K., The future of genetic studies of complex human diseases. Science 273 (1996), 1516–1517.
34. 34 Lander, E.S., Linton, L.M., Birren, B., et al., for the International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome [Errata in Nature 2001;411:720 and Nature 2001;412:565]. Nature 409 (2001), 860–921.
35. 35 Venter, J.C., Adams, M.D., Myers, E.W., et al. The sequence of the human genome. Science 291 (2001), 1304–1351.
36. 36 Sachidanandam, R., Weissman, D., Schmidt, S.C., et al., for the International SNP Map Working Group. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409 (2001), 928–933.
37. 37 Tabor, H.K., Risch, N.J., Myers, R.M., Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 3 (2002), 391–397.
38. 38 Wacholder, S., Chanock, S., Garcia-Closas, M., et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96 (2004), 434–442.
39. 39 Purcell, S., Cherny, S.S., Sham, P.C., Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19 (2003), 149–150.
40. 40 International HapMap Consortium. The International HapMap Project. Nature 426 (2003), 789–796.
41. 41 International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 449 (2007), 851–861.
42. 42 LaFramboise, T., Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. Nucleic Acids Res 37 (2009), 4181–4193.
43. 43 Hirschhorn, J.N., Daly, M.J., Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 6 (2005), 95–108.
44. 44 Hardy, J., Singleton, A., Genomewide association studies and human disease. N Engl J Med 360 (2009), 1759–1768.
45. 45 Chanock, S.J., Manolio, T., Boehnke, M., et al., for the NCI-NHGRI Working Group on Replication in Association Studies. Replicating genotype-phenotype associations. Nature 447 (2007), 655–660.
46. 46 McPherson, R., Pertsemlidis, A., Kavaslar, N., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 316 (2007), 1488–1491.
47. 47 Helgadottir, A., Thorleifsson, G., Manolescu, A., et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316 (2007), 1491–1493.
48. 48 Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 (2007), 661–678.
49. 49 Schunkert, H., Götz, A., Braund, P., et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation 117 (2008), 1675–1684.
50. 50 Shen, G.Q., Li, L., Rao, S., et al. Four SNPs on chromosome 9p21 in a South Korean population implicate a genetic locus that confers high cross-race risk for development of coronary artery disease. Arterioscler Thromb Vasc Biol 28 (2008), 360–365.
51. 51 Barbalic, M., Reiner, A.P., Wu, C., et al. Genome-wide association analysis of incident coronary heart disease (CHD) in African Americans: a short report. PLoS Genet, 7, 2011, e1002199.
52. 52 Franceschini, N., Hu, Y., Reiner, A.P., et al. Prospective associations of coronary heart disease loci in African Americans using the MetaboChip: the PAGE study. PLoS One, 9, 2014, e113203.
53. 53 Lettre, G., Palmer, C.D., Young, T., et al. Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet, 7, 2011, e1001300.
54. 54 Nikpay, M., Goel, A., Won, H.H., et al., for the CARDIoGRAMplusC4D Consortium. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 47 (2015), 1121–1130.
55. 55 Hannou, S.A., Wouters, K., Paumelle, R., et al. Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs?. Trends Endocrinol Metab 26 (2015), 176–184.
56. 56 Samani, N.J., Erdmann, J., Hall, A.S., et al., for the WTCCC and the Cardiogenics Consortium. Genomewide association analysis of coronary artery disease. N Engl J Med 357 (2007), 443–453.
57. 57 Erdmann, J., Grosshennig, A., Braund, P.S., et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet 41 (2009), 280–282.
58. 58 Gudbjartsson, D.F., Bjornsdottir, U.S., Halapi, E., et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 41 (2009), 342–347.
59. 59 Myocardial Infarction Genetics Consortium. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants [Erratum in Nat Genet 2009;41:762]. Nat Genet 41 (2009), 334–341.
60. 60 Trégouët, D.A., König, I.R., Erdmann, J., et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 41 (2009), 283–285.
61. 61 Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 43 (2011), 339–344.
62. 62 Schunkert, H., König, I.R., Kathiresan, S., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43 (2011), 333–338.
63. 63 Deloukas, P., Kanoni, S., Willenborg, C., et al., for the CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 45 (2013), 25–33.
64. 64 Lu, X., Wang, L., Chen, S., et al. Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet 44 (2012), 890–894.
65. 65 Takeuchi, F., Yokota, M., Yamamoto, K., et al. Genome-wide association study of coronary artery disease in the Japanese. Eur J Hum Genet 20 (2012), 333–340.
66. 66 Lee, J.Y., Lee, B.S., Shin, D.J., et al. A genome-wide association study of a coronary artery disease risk variant. J Hum Genet 58 (2013), 120–126.
67. 67 Aoki, A., Ozaki, K., Sato, H., et al. SNPs on chromosome 5p15.3 associated with myocardial infarction in Japanese population. J Hum Genet 56 (2011), 47–51.
68. 68 Hirokawa, M., Morita, H., Tajima, T., et al. A genome-wide association study identifies PLCL2 and AP3D1-DOT1L-SF3A2 as new susceptibility loci for myocardial infarction in Japanese. Eur J Hum Genet 23 (2015), 374–380.
69. 69 Ioannidis, J.P., Ntzani, E.E., Trikalinos, T.A., 'Racial' differences in genetic effects for complex diseases. Nat Genet 36 (2004), 1312–1318.
70. 70 Coram, M.A., Duan, Q., Hoffmann, T.J., et al. Genome-wide characterization of shared and distinct genetic components that influence blood lipid levels in ethnically diverse human populations. Am J Hum Genet 92 (2013), 904–916.
71. 71 Carlson, C.S., Matise, T.C., North, K.E., et al., for the PAGE Consortium. Generalization and dilution of association results from European GWAS in populations of non-European ancestry: the PAGE study. PLoS Biol, 11, 2013, e1001661.
72. 72 Keating, B.J., Tischfield, S., Murray, S.S., et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One, 3, 2008, e3583.
73. 73 Clarke, R., Peden, J.F., Hopewell, J.C., et al., for the PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361 (2009), 2518–2528.
74. 74 IBC 50K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet, 7, 2011, e1002260.
75. 75 Locke, A.E., Kahali, B., Berndt, S.I., et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 518 (2015), 197–206.
76. 76 Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nature Genet 45 (2013), 1274–1283.
77. 77 International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478 (2011), 103–109.
78. 78 Morris, A.P., Voight, B.F., Teslovich, T.M., et al., for the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 44 (2012), 981–990.
79. 79 Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 42 (2010), 441–447.
80. 80 Solovieff, N., Cotsapas, C., Lee, P.H., et al. Pleiotropy in complex traits: challenges and strategies. Nat Rev Genet 14 (2013), 483–495.
81. 81 Reich, D.E., Lander, E.S., On the allelic spectrum of human disease. Trends Genet 17 (2001), 502–510.
82. 82 Taylor, F., Huffman, M.D., Macedo, A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 1, 2013, CD004816.
83. 83 Rodriguez, F., Knowles, J.W., PCSK9 inhibition: current concepts and lessons from human genetics. Curr Atherosclerosis Rep, 17, 2015, 487.
84. 84 Fuster, V., Walsh, R.A., Harrington, R.A., (eds.) Hurst's The Heart, 13th edition, 2011, McGraw-Hill, New York, NY.
85. 85 Mann, D.L., Zipes, D.P., Libby, P., Bonow, R.O., Braunwald, E., (eds.) Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10th edition, 2015, Elsevier/Saunders, Philadelphia, PA.
86. 86 Hong, M.K., Mintz, G.S., Lee, C.W., et al. Plaque ruptures in stable angina pectoris compared with acute coronary syndrome. Int J Cardiol 114 (2007), 78–82.
87. 87 Hong, M.K., Mintz, G.S., Lee, C.W., et al. Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: a three-vessel intravascular ultrasound study in 235 patients. Circulation 110 (2004), 928–933.
88. 88 Burke, A.P., Kolodgie, F.D., Farb, A., et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103 (2001), 934–940.
89. 89 Reilly, M.P., Li, M., He, J., et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 377 (2011), 383–392.
90. 90 Gill, J.C., Endres-Brooks, J., Bauer, P.J., et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69 (1987), 1691–1695.
91. 91 Spiel, A.O., Gilbert, J.C., Jilma, B., von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 117 (2008), 1449–1459.
92. 92 Dandona, S., Stewart, A.F., Chen, L., et al. Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol 56 (2010), 479–486.
93. 93 Chan, K., Patel, R.S., Newcombe, P., et al. Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. J Am Coll Cardiol 61 (2013), 957–970.
94. 94 Bjornsson, E., Gudbjartsson, D.F., Helgadottir, A., et al. Common sequence variants associated with coronary artery disease correlate with the extent of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 35 (2015), 1526–1531.
95. 95 Bentzon, J.F., Otsuka, F., Virmani, R., et al. Mechanisms of plaque formation and rupture. Circ Res 114 (2014), 1852–1866.
96. 96 Salfati, E., Nandkeolyar, S., Fortmann, S.P., et al. Susceptibility loci for clinical coronary artery disease and subclinical coronary atherosclerosis throughout the life-course. Circ Cardiovasc Genet 8 (2015), 803–811.
97. 97 Burgess, S., Thompson, S.G., Mendelian Randomization: Methods for Using Genetic Variants in Causal Estimation. 2015, Chapman & Hall/CRC, Boca Raton, FL.
98. 98 Lawlor, D.A., Davey Smith, G., Kundu, D., et al. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?. Lancet 363 (2004), 1724–1727.
99. 99 Voight, B.F., Peloso, G.M., Orho-Melander, M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380 (2012), 572–580.
100. 100 Jansen, H., Samani, N.J., Schunkert, H., Mendelian randomization studies in coronary artery disease. Eur Heart J 35 (2014), 1917–1924.
101. 101 Keene, D., Price, C., Shun-Shin, M.J., et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ, 349, 2014, g4379.
102. 102 Stability Investigators. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 370 (2014), 1702–1711.
103. 103 Nicholls, S.J., Kastelein, J.J., Schwartz, G.G., et al., for the VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 311 (2014), 252–262.
104. 104 O'Donoghue, M.L., Braunwald, E., White, H.D., et al., for the SOLID-TIMI 52 Investigators. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 312 (2014), 1006–1015.
105. 105 Yang, H.T., Lee, M., Hong, K.S., et al. Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta-analysis of randomized controlled trials. Eur J Intern Med 23 (2012), 745–754.
106. 106 Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al., for the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
107. 107 Walz, C.P., Barry, A.R., Koshman, S.L., Omega-3 polyunsaturated fatty acid supplementation in the prevention of cardiovascular disease. Can Pharm J (Ott) 149 (2016), 166–173.
108. 108 Nicholls SJ. Assessment of clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at a high risk for vascular outcomes—ACCELERATE. Paper presented at: American College of Cardiology Annual Scientific Session; April 3, 2016; Chicago, IL.
109. 109 Pierce, B.L., Van der Weele, T.J., The effect of non-differential measurement error on bias, precision and power in Mendelian randomization studies. Int J Epidemiol 41 (2012), 1383–1393.
110. 110 Kathiresan, S., Melander, O., Anevski, D., et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358 (2008), 1240–1249.
111. 111 Lieb, W., Jansen, H., Loley, C., et al. Genetic predisposition to higher blood pressure increases coronary artery disease risk. Hypertension 61 (2013), 995–1001.
112. 112 Ference, B.A., Yoo, W., Alesh, I., et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 60 (2012), 2631–2639.
113. 113 Khera, A.V., Won, H.H., Peloso, G.M., et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 67 (2016), 2578–2589.
114. 114 Burgess, S., Bowden, J., Fall, T., Ingellson, E., Thompson, S.G., Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology 28 (2017), 30–42.
115. 115 Bowden, J., Davey Smith, G., Burgess, S., Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 44 (2015), 512–525.
116. 116 Burgess, S., Harshfield, E., Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future. Curr Opin Endocrinol Diabetes Obes 23 (2016), 124–130.
117. 117 Manolio, T.A., Genomewide association studies and assessment of the risk of disease. N Engl J Med 363 (2010), 166–176.
118. 118 Thanassoulis, G., Vasan, R.S., Genetic cardiovascular risk prediction: will we get there?. Circulation 122 (2010), 2323–2334.
119. 119 Berger, J.S., Jordan, C.O., Lloyd-Jones, D., et al. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 55 (2010), 1169–1177.
120. 120 Barlow, W.E., White, E., Ballard-Barbash, R., et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 98 (2006), 1204–1214.
121. 121 Vasan, R.S., Sullivan, L.M., Wilson, P.W., et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors [Erratum in Ann Intern Med 2005;142:681]. Ann Intern Med 142 (2005), 393–402.
122. 122 Goff, D.C. Jr., Lloyd-Jones, D.M., Bennett, G., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Erratum in J Am Coll Cardiol 2014;63:3026]. J Am Coll Cardiol 63 (2014), 2935–2959.
123. 123 Goldstein, B.A., Knowles, J.W., Salfati, E., et al. Simple, standardized incorporation of genetic risk into non-genetic risk prediction tools for complex traits: coronary heart disease as an example. Front Genet, 5, 2014, 254.
124. 124 Morrison, A.C., Bare, L.A., Chambless, L.E., et al. Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 166 (2007), 28–35.
125. 125 Wilson, P.W., Challenges to improve coronary heart disease risk assessment. JAMA 302 (2009), 2369–2370.
126. 126 Cook, N.R., Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 54 (2008), 17–23.
127. 127 Mega, J.L., Stitziel, N.O., Smith, J.G., et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 385 (2015), 2264–2271.
128. 128 Krarup, N.T., Borglykke, A., Allin, K.H., et al. A genetic risk score of 45 coronary artery disease risk variants associates with increased risk of myocardial infarction in 6041 Danish individuals. Atherosclerosis 240 (2015), 305–310.
129. 129 Ganna, A., Magnusson, P.K., Pedersen, N.L., et al. Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol 33 (2013), 2267–2272.
130. 130 Tada, H., Melander, O., Louie, J.Z., et al. Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur Heart J 37 (2016), 561–567.
131. 131 Abraham, G., Havulinna, A.S., Bhalala, O.G., et al. Genomic prediction of coronary heart disease. Eur Heart J, 2016 Sep 21 [E-pub ahead of print].
132. 132 Kerr, K.F., Wang, Z., Janes, H., et al. Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology 25 (2014), 114–121.
133. 133 Pepe, M.S., Janes, H., Li, C.I., Net risk reclassification P values: valid or misleading?. J Natl Cancer Inst, 106, 2014, dju041.
134. 134 Pepe, M.S., Kerr, K.F., Longton, G., et al. Testing for improvement in prediction model performance. Stat Med 32 (2013), 1467–1482.
135. 135 Težak, Z., Kondratovich, M.V., Mansfield, E., US FDA and personalized medicine: in vitro diagnostic regulatory perspective. Per Med 7 (2010), 517–530.
136. 136 Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378 (2011), 771–784.
137. 137 Agarwala, V., Flannick, J., Sunyaev, S., Altshuler, D., Evaluating empirical bounds on complex disease genetic architecture. Nat Genet 45 (2013), 1418–1427.
138. 138 Park, J.H., Gail, M.H., Weinberg, C.R., et al. Distribution of allele frequencies and effect sizes and their interrelationships for common genetic susceptibility variants. Proc Natl Acad Sci U S A 108 (2011), 18026–18031.
139. 139 Lee, S.H., Yang, J., Chen, G.B., et al. Estimation of SNP heritability from dense genotype data. Am J Hum Genet 93 (2013), 1151–1155.
140. 140 Fuchsberger, C., Flannick, J., Teslovich, T.M., et al. The genetic architecture of type 2 diabetes. Nature 536 (2016), 41–47.
141. 141 Manolio, T.A., Collins, F.S., Cox, N.J., et al. Finding the missing heritability of complex diseases. Nature 461 (2009), 747–753.
142. 142 van Dijk, E.L., Auger, H., Jaszczyszyn, Y., et al. Ten years of next-generation sequencing technology. Trends Genet 30 (2014), 418–426.
143. 143 Kim, D.W., Nam, S.H., Kim, R.N., et al. Whole human exome capture for high-throughput sequencing. Genome 53 (2010), 568–574.
144. 144 Fu, W., O'Connor, T.D., Jun, G., et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature 493 (2013), 216–220.
145. 145 Guo, Y., He, J., Zhao, S., et al. Illumina human exome genotyping array clustering and quality control. Nat Protoc 9 (2014), 2643–2662.
146. 146 Auer, P.L., Lettre, G., Rare variant association studies: considerations, challenges and opportunities. Genome Med, 7, 2015, 16.
147. 147 Do, R., Stitziel, N.O., Won, H.H., et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518 (2015), 102–106.
148. 148 TG and HDL Working Group of the Exome Sequencing Project, National Heart Lung Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371 (2014), 22–31.
149. 149 Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 371 (2014), 2072–2082.
150. 150 Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med 374 (2016), 1134–1144.
151. 151 Robinson, J.G., Farnier, M., Krempf, M., et al., for the ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1489–1499.
152. 152 Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., et al., for the Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372 (2015), 1500–1509.
153. 153 Do, R., Willer, C.J., Schmidt, E.M., et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 45 (2013), 1345–1352.
154. 154 Burgess, S., Freitag, D.F., Khan, H., et al. Using multivariable Mendelian randomization to disentangle the causal effects of lipid fractions. PLoS One, 9, 2014, e108891.
155. 155 C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ, 342, 2011, d548.
156. 156 Kathiresan, S., Developing medicines that mimic the natural successes of the human genome: lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETP. J Am Coll Cardiol 65 (2015), 1562–1566.
157. 157 Xie, X., Zheng, Y.Y., Adi, D., et al. Exome sequencing in a family identifies RECQL5 mutation resulting in early myocardial infarction. Medicine (Baltimore), 95, 2016, e2737.
158. 158 Abramowitz, Y., Roth, A., Keren, G., et al. Whole-exome sequencing in individuals with multiple cardiovascular risk factors and normal coronary arteries. Coronary Artery Dis 27 (2016), 257–266.
159. 159 Tak, Y.G., Farnham, P.J., Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome. Epigenetics Chromatin, 8, 2015, 57.
160. 160 National Heart, Lung, and Blood Institute. NHLBI Trans-Omics for Precision Medicine Whole Genome Sequencing Program. 2016. Available at: https://www.nhlbiwgs.org/. Accessed October 24, 2016.
161. 161 National Human Genome Research Institute. NHGRI Genome Sequencing Program (GSP): Centers for Common Disease Genomics. 2016. Available at: https://www.genome.gov/27563570. Accessed October 24, 2016.
162. 162 Allen, N.E., Sudlow, C., Peakman, T., et al., for the Biobank UK. UK biobank data: come and get it. Sci Transl Med, 6, 2014, 224ed4.
163. 163 Chen, Z., Chen, J., Collins, R., et al., for the China Kadoorie Biobank (CKB) Collaborative Group. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol 40 (2011), 1652–1666.
164. 164 Gaziano, J.M., Concato, J., Brophy, M., et al. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J Clin Epidemiol 70 (2016), 214–223.
165. 165 Shah, S.H., Arnett, D., Houser, S.R., et al. Opportunities for the cardiovascular community in the precision medicine initiative. Circulation 133 (2016), 226–231.
166. 166 Musunuru, K., Strong, A., Frank-Kamenetsky, M., et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 466 (2010), 714–719.
167. 167 Kjolby, M., Andersen, O.M., Breiderhoff, T., et al. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab 12 (2010), 213–223.
168. 168 Kessler, T., Zhang, L., Liu, Z., et al. ADAMTS-7 inhibits re-endothelialization of injured arteries and promotes vascular remodeling through cleavage of thrombospondin-1. Circulation 131 (2015), 1191–1201.
169. 169 Bauer, R.C., Tohyama, J., Cui, J., et al. Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice. Circulation 131 (2015), 1202–1213.
170. 170 Nurnberg, S.T., Zhang, H., Hand, N.J., et al. From loci to biology: functional genomics of genome-wide association for coronary disease. Circ Res 118 (2016), 586–606.
171. 171 Zhao, Y., Chen, J., Freudenberg, J.M., et al. Network-based identification and prioritization of key regulators of coronary artery disease loci. Arterioscler Thromb Vasc Biol 36 (2016), 928–941.
172. 172 Miller, C.L., Pjanic, M., Wang, T., et al. Integrative functional genomics identifies regulatory mechanisms at coronary artery disease loci. Nat Commun, 7, 2016, 12092.
173. 173 Pjanic, M., Miller, C.L., Wirka, R., et al. Genetics and genomics of coronary artery disease. Curr Cardiol Rep, 18, 2016, 102.
174. 174 Cunnington, M.S., Keavney, B., Genetic mechanisms mediating atherosclerosis susceptibility at the chromosome 9p21 locus. Curr Atheroscler Rep 13 (2011), 193–201.
175. 175 Swerdlow, D.I., Hingorani, A.D., Humphries, S.E., Genetic risk factors and Mendelian randomization in cardiovascular disease. Curr Cardiol Rep, 17, 2015, 33.
176. 176 Wang, F., Xu, C.Q., He, Q., et al. Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population. Nat Genet 43 (2011), 345–349.